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Abstract
Equine herpesvirus-1 (EHV-1) infection is of significant animal welfare and economic importance. Yet, no standardised molecular
techniques are available for diagnosis or confirmation of viral infection. The purpose of this study was to develop a standardised and
quantitative assay system for the reliable detection of EHV-1 infection which was capable of eliminating the likelihood of false
negative results. A region within the EHV-1 glycoprotein B gene was amplified by polymerase chain reaction (PCR), cloned and
subjected to site-directed mutagenesis to generate a control plasmid, amplifiable by identical primers to wild type EHV-1, yet
capable of detection by an alternate dinitrophenylated oligonucleotide probe in a PCR/ELISA system. A competitive PCR/ELISA
system which can control for the presence of PCR inhibitors and which is capable of detecting 63 genome equivalents of EHV-1 has
been developed. EHV-1 presence in infected equine tissue and cell culture material was demonstrated using this system. The entire
assay can be completed within one working day and facilitates multiple sample analysis. The availability of a robust, competitive
PCR/ELISA system for the detection of EHV-1 will facilitate the rapid and sensitive detection of EHV-1 and offers the potential
for eliminating the occurrence of abortion storms in stud farms.
# 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
The alphaherpesvirus, equine herpesvirus-1 (EHV-1),
is the causative agent of respiratory disease, abortion
and neurological disorders in horses (Allen and Bryans
1986; Crabb and Studdert, 1995). Originally EHV-1 was
designated as rhinopneumonitis virus, however exam-
ination of restriction endonuclease DNA fingerprints by
Studdert et al. (1981) showed two distinct virus subtypes
namely EHV-1 and EHV-4. While EHV-4 is restricted
to the respiratory epithelium and lymph nodes draining
the lung, EHV-1 is distinct in that it spreads systemically
resulting in post-respiratory complications including
abortion and paralysis (Wagner et al., 1992; Lawrence
et al., 1994). Due to the ability of EHV-1 to cause
‘abortion storms’ in mares after fetal infection (Studdert
and Blackney 1979; Crabb and Studdert, 1995) diag-
nosis of EHV-1 must be rapid and sensitive so that early
intervention policies, aimed at reducing the effect of
virus spread, can be put in place (Ballagi-Pordany et al.,
1990; Sharma et al., 1992; Lawrence et al., 1994; Gupta
et al., 1996).
The development of the polymerase chain reaction
(PCR) has lead to improved detection of EHV-1 DNA
from clinical and cell culture material (Kirisawa et al.,
1993). Amplification of viral DNA by PCR can be
further enhanced by hybridisation with viral specific
DNA probes (Lawrence et al., 1994; Welch et al., 1992;
Kirisawa et al., 1993) and also by restriction endonu-
clease digestion (Allen et al., 1983; Morris and Field,
1988; Palfi and Christensen, 1995). However, the
extraction of viral DNA from samples may also lead
to the co-purification of PCR inhibitors (Zerbini et al.,
1999). The presence of inhibitory molecules in a PCR
reaction suppress Taq polymerase activity, preventing
the amplification of viral DNA and thus leads to false
negative results (Barber et al., 1999). A method of
determining the presence of PCR inhibitors is co-
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amplification of a control plasmid with the target DNA
using identical primers pairs (Barber et al., 1999; Zerbini
et al., 1999; Drews et al., 2000). The control plasmid
contains a short mutagenised DNA sequence and
amplicons of target and control can be distinguished
from each other, post-PCR, using type-specific oligonu-
cleotide probes in an ELISA.
In the present study, the development of a robust
competitive PCR/ELISA system for the detection of
EHV-1 is described. The control plasmid was con-
structed by the introduction of a heterogeneous dini-
trophenol (DNP)-labelled oligonucleotide probe
sequence by site-directed mutagenesis (SDM). The
rapid, competitive PCR/ELISA assay displayed high
levels of sensitivity and specificity detecting as little as 63
genome equivalents of EHV-1.
2. Materials and methods
2.1. EHV-1 viral strains and viral DNA extraction
EHV-1 wild type (wt) strain Ab4p (obtained from Dr
Josh Slater, Queens Veterinary School Hospital, Uni-
versity of Cambridge, UK) was originally isolated from
a field case of abortion and paralysis in a mare and is
regarded as a pathogenic strain of EHV-1. The virus was
supplied as a concentrated mixture of virus in lysed ED
cells with a viral copy number (genome equivalent) of
approximately 1010, as determined by plaque assay.
EHV-1 tissue homogenates (provided by Dr Werner
Eichhorn, Mu¨nchen, Germany) were isolated from fetal
liver, lung and spleen. Positive EHV-1 tissue samples (by
IF and isolation) were labelled S726-8, S685-7 and 835-7
and negative tissue samples labelled S611-3, S723-5 and
597-9. EHV-1 wt strain Ab4p (5 ml lysate) and tissue
homogenate (5 ml) were extracted using the Qiagen
QIAamp spin column DNA midi kit extraction protocol
(Qiagen, Hilden, Germany) (final volume: 200 ml). DNA
extraction was performed in separate area to that of
PCR reagent preparation and nucleic acid amplification.
2.2. EHV-1 oligonucleotide primers
The viral DNA was amplified by using specific
oligonucleotide primers selected from the glycoprotein
B (gB) region of the EHV-1 genome. The primer
sequences were selected based on results obtained by
Kirisawa et al. (1993). The 20 base biotinylated (B)
forward primer sequence (P1) was compatible with both
EHV-1 and EHV-4 while the reverse 20 base sequence
(P2) was compatible with only EHV-1. The 5? biotiny-
lated nucleotide sequences for the forward primer P1
was: 5?-B-CTTGTGAGATCTAACCGCAC-3? and un-
modified reverse P2 primer was: 5?-GCGTTATAGC-
TATCACGTCC-3? (Sigma-Genosys, Cambridge, UK).
2.3. Amplification of DNA
A total of 5 ml of each DNA sample was used in each
PCR reaction with 10 mM Tris/HCl pH 9.0, 50 mM
KCl, 0.1% (v/v) Triton X-100, 1.5 mM MgCl2, 200 mM
of each dNTP (Promega, WI, USA), 1 M Betaine
(Sigma, Dorset, UK), 1.0 mM of the above primers in
a total volume of 49.5 ml. Hot-start PCR was performed
on each sample by adding 0.5 ml of Taq polymerase
(Promega) after the initial 6 min denaturation step at
95 8C. The PCR reaction was then continued with 35
cycles consisting of 1 min denaturation at 95 8C, primer
annealing at 55 8C for 1 min, extension at 72 8C for 2
min and finally extension for 5 min at 72 8C. PCR
amplified DNA was analysed by agarose gel electro-
phoresis whereby 10 ml of product was ran on 1% (w/v)
agarose (Promega) containing 0.5 mg/ml of ethidium
bromide (Sigma, Dorset) for 30 min at 100 V. Visualisa-
tion of the 460 bp P1/P2 amplicons was performed
using an ‘Eagle-Eye II’ digital still video system (Stra-
tagene, CA, USA).
2.4. Construction of EHV-1 gB plasmid
EHV-1 gB P1/P2 amplicons were purified using the
Strata Prep PCR purification kit (Stratagene). Purified
PCR products were cloned into the pCR-2.1 TOPO
vector (Invitrogen, Groningen, NL) following manufac-
turers’ instructions and transformed into competent E.
coli . Following purification (Qiagen plasmid purifica-
tion kit, Qiagen), the gB plasmid was subjected to PCR
using plasmid-specific M13 primers supplied by the
manufacturer and products screened by restriction
digestion with EcoRI and BamHI enzymes. The M13
PCR products were sequenced using a Perkin Elmer
ABI Prism 310 genetic analyser and sequence homology
was determined with that of the known wt EHV-1 gB
sequence using the BLAST algorithm (http://
www.ncbi.nlm.nih.gov/blast/bl2seq/bl2.html).
2.5. Construction of competitive internal control plasmid
A modification of the method of Barber et al. (1999)
for SDM was employed in the design of the control
plasmid which involved replacing a 30 bp sequence of
the gB plasmid with a heterogenous sequence of similar
Tm and deoxynucleotide composition (Fig. 1). The
forward 40-mer primer (mutant DNP) contained the
control probe site. The first 10 bases at the 3? end of the
‘mutant DNP’ primer was complementary to the EHV-1
gB sequence while the remaining 30 bases formed a 5?
overhang which incorporated the control probe site
(Fig. 1). The sequence of the mutant DNP primer was:
5?-CTCAAGAAGACctgcagTCtctaga GGAACTCCAA-
CGTCA-3? (note: the control probe site in bold). Two
restriction sites, PstI and XbaI were incorporated into
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the control probe sequence, which allowed for selection
of control plasmid (shown in small font). The 20-mer
‘reverse back/back’ primer shown below was phos-
phorylated at the 5? end (5?-þ-CCTCCACTGCTC-
GTTTGTGT-3?). Inverse PCR was carried out using
2.5 U of Pfu polymerase, in a total volume of 50 ml with
1.0 mM of each of the above forward ‘mutant DNP’ and
‘reverse back/back’ primer, 20 mM Tris/HCl pH 8.8,
10 mM KCl, 10 mM (NH4)2SO4, 2 mM MgSO4, 0.1%
(v/v) Triton X-100, 5 mg BSA, 1.5 mM MgCl2, 200 mM
of each dNTP and 1 ml template (gB plasmid: 70 mg/ml).
Cycle conditions were initial 4 min denaturation step at
95 8C. The PCR reaction was then continued with 20
cycles consisting of 1 min denaturation at 95 8C, primer
annealing at 60 8C for 2 min, extension at 72 8C for 7
min. Ten microlitre of PCR product was removed and
gB plasmid digested for 30 min at 37 8C with DpnI (10
U) in SuRE/Cut buffer (33 mM Tris acetate, 66 mM
potassium acetate, 10 mM magnesium acetate, 0.5 mM
DTT, pH 7.9). The linear control plasmid was then
ligated and cloned into one-shot competent E. coli and
colonies selected for the presence of the plasmid by PCR
using the P1/P2 primers pairs. The control probe-
specific restriction sites (XbaI and PstI) were subse-
quently used to screen and select P1/P2 positive
colonies for the correct control probe site sequence.
Purified gB and control plasmids were diluted 1/100 in
sterile water (DNA/RNA free) and the O.D. 260/280 nm
measured using a Beckman DU 640 Spectrophotometer.
O.D. 260/dilution factor/50/concentration of
DNA in mg/ml.
2.6. PCR/ELISA procedure
Microwells (Nunc, Roskilde, Denmark) were coated
with streptavidin (2.5 mg/ml) and stabilised for 4 8C
storage by the addition of 1% (w/v) BSA in 50 mM
sodium carbonate buffer pH 9.4. P1/P2 PCR products
(5 ml) were transferred in duplicate to streptavidin
coated microtitre plates in 95 ml 6X SSC (0.9 M NaCl,
0.09 M sodium citrate solution). The biotinylated
amplicons were left to attach for 30 min at 37 8C.
Wells were washed twice with phosphate buffered saline
containing 0.05% (v/v) Tween-20 (PBST) and 100 ml of
melting solution (0.125 M NaOH, 0.1 M NaCl) was
added to the microwells to dissociate DNA duplex,
incubated at room temperature for 3 min and washed
four times with PBST. Then, 100 ml of either the gB or
Fig. 1. Inverse PCR method for SDM showing the individual steps involved in the generation of a control plasmid. ‘Mutant DNP’ refers to an
oligonucleotide containing a complementary sequence to which the control DNP probe binds.
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the control complementary DNP oligonucleotide probe
(100 ng/ml) in 6X SSC/0.1% (w/v) SDS was hybridised
to the biotinylated forward strand at 60 8C for 1 h
followed by washing four times with PBST. The DNP
oligonucleotide probe was designed to be complemen-
tary to the gB or control sequences described above. The
DNP probes (OSWEL, Southampton, UK) nucleotide
sequences were: gB probe: 5?(DNP)3-TGACGTTGG-
AAGAATCGGTACCTGCCATTG-3?; control probe:
5?(DNP)3-GTTCCTCTAGAGACTGCAGGTCTTCT-
TGAG-3?. After hybridisation of the DNP probes wells
were washed four times and blocked for 10 min with
2.5% (w/v) milk powder in PBST. Following removal of
the blocking solution, IgG[anti-DNP]-horseradish per-
oxidase conjugate was added, incubated at room
temperature for 30 min and washed four times with
PBST. Substrate (100 ml tetramethylbenzidine) was then
added and incubated for 15 min at room temperature.
The reaction was terminated by the addition of 1 N
sulphuric acid and measured spectrophotometrically at
450/630 nm (Dynatech MRX).
2.7. Competitive PCR/ELISA assay
Preliminary experiments involved amplification of the
P1/P2 fragments from serial dilutions of gB and control
templates in non-competitive assays to determine opti-
mal copy number detection. Assay sensitivity was
determined using different probe associations (i.e., gB
probe alone, gB and control probe together and control
probe alone). Following optimisation of PCR/ELISA
conditions, serial dilutions of gB plasmid were co-
amplified with known different amounts of control
(data not shown). The selected concentration of control
plasmid used in the competitive PCR/ELISA was
established by determining optimal levels of gB target
DNA detection whilst not suppressing the detection of
the control. Following determination of the optimal
control plasmid copy number in the competitive PCR/
ELISA assay, validation of the assay involved co-
amplifying 1000 copies of control with purified wt
Ab4p EHV-1 and positive/negative EHV-1 fetal liver
lung and spleen tissue samples. Finally, a known PCR
inhibitor (sodium iodide) was used to assess the efficacy
of the competitive control plasmid in the PCR/ELISA.
3. Results
3.1. Generation of gB and internal control plasmids
The EHV-1 P1/P2 PCR product (460 bp), derived
from wt EHV-1 strain Ab4p, was purified and cloned
into the pCR-2.1 vector and competent one-shot E. coli
were subsequently transformed. Resultant M13 for-
ward-reverse amplicons were of the correct size (661
bp) and subsequent digestion with BamHI and EcoRI
yielded 613 and 478 bp products, respectively (data not
shown). Sequence analysis of the purified gB plasmid
revealed the correct orientation of the P1/P2 fragment
in the pCR-2.1 TOPO vector. PCR and restriction
analysis of the plasmid derived from SDM of the gB
plasmid resulted in the generation of the correct P1/P2
amplicon size that was susceptible to digestion with both
XbaI and PstI (Fig. 2), was thus selected as the internal
control plasmid for PCR/ELISA optimisation.
3.2. Competitive PCR/ELISA
Serial dilutions of the gB plasmid from 102/104 copies
were amplified in the absence, and presence, of dilutions
of control plasmid to determine the minimum copy
number of competitor required for detection by PCR/
ELISA whilst not inhibiting the amplification efficiency
of the target. A minimum of 100 molecules of either
plasmid was required for reliable detection (Fig. 3 and
data not shown). Furthermore, comparable amplifica-
tion efficiency was recorded between the target and the
control at similar copy numbers. Lower copy numbers
of each plasmid failed to result in any detectable P1/P2
amplicons by either PCR/ELISA or gel electrophoresis
(Fig. 3 and data not shown). A total of 10 000 copies of
the control when co-amplified with serial dilutions of gB
plasmid caused a reduction in the sensitivity of detection
as determined by PCR/ELISA when compared to that
of gB amplified alone (Fig. 3). In contrast, when 1000
copies of control was co-amplified with gB plasmid, no
significant difference in amplification efficiency of target
gB in the competitive reaction or when gB was amplified
alone could be detected (Fig. 3). At 1000 copies of
control, as low as 100 copies of gB plasmid were readily
detected in the competitive assay and this level of
control was subsequently used in the competitive
PCR/ELISA. No significant cross-reactivity was ob-
served between gB/control DNP probe and the gB/
control PCR products as determined by hybridisation of
non-homologous probes with amplicons (Fig. 3 and
data not shown).
3.3. Competitive PCR/ELISA assay for the detection of
wt EHV-1
To evaluate the efficiency of the competitive PCR/
ELISA assay, 1000 copies of control were co-amplified
with serial dilutions of extracted wt EHV-1, and tissue
samples. All samples were extracted using Qiagen spin
columns and subsequently serially diluted to 1/106.
Each dilution was amplified alone or co-amplified with
1000 copies of control plasmid. Amplification of in-
dividual wt EHV-1 serial dilutions (from a viral stock of
1010 genome equivalents EHV-1) resulted in endpoint
detection at a 105 dilution, which equates to 63
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genome equivalents of EHV-1 (Fig. 4). In the competi-
tive assay, control amplification was out-competed by
the large amounts of wt EHV-1 in the range from neat
to 103 dilution. From 104 to 106 wt dilutions, the
levels of control amplification increased with decreasing
wt concentration. Due to amplification of wt EHV-1 at
high concentrations and control at low target levels,
these results demonstrate that no PCR inhibitors were
present in any of the serial dilutions tested.
3.4. Validation of the PCR/ELISA
The competitive PCR/ELISA was validated by
examination of EHV-1 positive and negative fetal tissue
homogenate samples isolated from fetal liver, lung and
spleen. Samples labelled S726-8, S685-7 and 835-7 were
positive by PCR/ELISA while samples S611-3, S723-5
and 597-9 were negative (Fig. 5). The results obtained
here correlated with gel electrophoresis analysis (data
not shown) and immunofluorescent assay/virus isolation
studies by Dr Werner Eichhorn (personal communica-
tion). Co-amplification of 1000 copies of control with
extracted negative EHV-1 tissue samples (S611-3, S723-
5 and 597-9) resulted in the detection of the control
amplicon in all three negative samples (Fig. 5). In the
positive tissue samples, control amplification was not
observed due to the high template EHV-1 levels which
out-competed the control for P1/P2 primer binding. At
a concentration of 50 mM NaI, amplification was
completely inhibited while at 5 mM NaI, the inhibitory
effect was almost completely removed with absorbance
values approaching that of control only (Fig. 5).
4. Discussion
In this report we describe a rapid and sensitive
competitive PCR/ELISA method which can detect 63
genome equivalents of EHV-1 from culture and clinical
specimens.
To date, only a limited number of reports detail the
relative sensitivities of the oligonucleotide primers in
EHV-1 PCR detection assays whereby the sensitivities of
the PCR assays using ‘hot-start’ PCR (Osterrieder et al.,
1994) or nested PCR (Kirisawa et al. 1993; Borchers and
Slater, 1993) using ethidium bromide/agarose gel elec-
trophoresis detection was 100, 10 copies and 1/3 copies
of EHV-1, respectively. In addition, a major complica-
tion in the diagnosis of viral infections by PCR is the
presence of Taq polymerase inhibitors that lead to false
negative results (Courtney et al., 1999; Barber et al.,
1999). The presence of such inhibitors can be monitored
by the incorporation of a competitive control plasmid
(Courtney et al., 1999). Thus, both the target and
control are affected equally by variation in amplification
efficiency (Drews et al., 2000). Furthermore, the incor-
poration of a hybridisation probe in an ELISA format
generally increases the specificity and sensitivity of the
PCR assay and eliminates analysis by gel electrophor-
esis.
Fig. 2. Analysis of control plasmid and resultant PCR products by agarose gel electrophoresis. Lanes 1/2: DpnI -digested control (lane 1) and gB
plasmids (lane 2), respectively; lane 3: P1/P2 PCR product from control plasmid (460 bp); lane 4: XbaI digestion of control P1/P2 amplicon (189
and 271 bp); lane 5: PstI digestion of control P1/P2 amplicon (185 and 275 bp); lane 6: P1/P2 PCR product from gB plasmid; lane 7: negative
control; Lane 8: 10 kb molecular weight marker.
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Based on PCR/ELISA results obtained, the mini-
mum detection level was estimated at 100 copies of gB
plasmid and 63 genome equivalents of EHV-1, respec-
tively. The slightly higher sensitivity of detection ob-
served with EHV-1 DNA may reflect the presence of
non-specific carrier DNA in the preparation which
prevents absorptive DNA loss onto tube walls. Compar-
able amplification efficiencies of gB target and control,
at identical copy numbers, were evident which is a
fundamental requirement of the competitive PCR assay.
In order to determine the optimal copy number of
control to be used in the competitive PCR/ELISA,
competition assays were performed between the gB and
control plasmids, respectively. Based on results ob-
tained, 1000 copies of the control were found to be
optimal for detection of EHV-1 gB amplicons without
suppressing the sensitivity of target detection. Barber et
al. (1999) recorded similar results using competitive
internal control at 1000 copies in a PCR/ELISA to
detect human cytomegalovirus blood samples of heart
and lung transplant recipients.
The clinical utility of the competitive PCR/ELISA
assay was assessed by the co-amplification of 1000
copies of control with EHV-1 positive/negative fetal
Fig. 3. Competitive PCR/ELISA with (A) 10 000 or (B) 1000 copies of control plasmid in the presence of varying amounts of EHV-1 gB plasmid.
EHV-1 gB plasmid copy number ranged from 102/104 and was amplified alone (*/o*/) or in the presence of control plasmid (dark and light boxes)
at the aforementioned amounts. The control DNP oligonucleotide probe was unreactive to gB-derived amplicons (*/x*/).
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tissue samples. Positive EHV-1 fetal tissue samples
(S726-8, S685-7 and 835-7) resulted in the detection of
high levels of EHV-1 amplicons by PCR/ELISA using
gB-specific DNP oligonucleotide probes while negligible
levels of control amplicons were recorded. These results
demonstrate the competitive nature of the templates for
the P1/P2 primers where the control was out-competed
by the high concentrations of EHV-1 in positive tissue
samples. All three EHV-1 negative fetal tissue samples
(S611-3, S723-5 and 597-9) analysed by PCR/ELISA
Fig. 4. Competitive PCR/ELISA analysis of wt EHV-1 at various dilutions. Log dilutions of purified EHV-1 DNA were amplified alone (*/o*/) or
co-amplified with 1000 copies of the control plasmid (dark and light boxes). It is apparent that high levels of EHV-1 DNA inhibit control
amplification (Neat*/103 dilutions). Control amplification is evident at dilutions greater than 104 wt EHV-1 DNA. The PCR/ELISA cut-off
value (0.140) was calculated from the mean negative specimen absorbance/2 standard deviations (0.095/2(0.0225); N/12).
Fig. 5. Evaluation of EHV-1 positive and negative clinical specimens by PCR/ELISA. Confirmed EHV-1 positive (S726-8, S685-7 and 835-7) and
negative (S611-3, S723-5 and 597-9) tissue samples, by immunofluorescence and virus isolation, gave the expected result following blinded testing by
PCR/ELISA. The effect of the PCR inhibitor, NaI, was investigated at 5 and 50 mM, respectively, in PCR reactions containing 1000 copies each of
gB and control plasmid. No amplification was evident at 50 mM NaI. The PCR/ELISA cut-off value (0.140) is indicated by the solid line.
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were control amplicon positive and negative for gB
amplicons. Thus, the negative tissue samples were true
negatives due to the successful amplification of the
control. However, negative samples S611-3 and S723-5
in the competitive PCR/ELISA had significantly lower
absorbance readings than that of sample 597-9 and 1000
copies of control alone. This suggests that there may be
low concentrations of PCR inhibitors extracted from
these tissue samples. To demonstrate the potential of the
control in the PCR/ELISA to detect potent Taq
polymerase inhibitors, the effect of NaI at different
concentrations was investigated. The presence of high
concentration of NaI (50 mM) completely inhibited the
amplification of gB and control as determined by the
absence of signals on the ELISA. The effect of reducing
the concentration of inhibitor (5 mM) relieved the
inhibitory effect NaI and resulted in control detection
in the PCR/ELISA.
Since EHV-1 is believed to persist following initial
infection, the competitive PCR/ELISA developed here
could be used to determine the actual viral load in the
pregnant mare. Viral loads may correspond to the stage
of disease and could be used as a marker for disease
progression. It is currently unclear if serial surveillance
can be used to monitor the progress of EHV-1 infections
in horses and the EHV-1 PCR/ELISA presented here
may provide a useful tool to investigate this situation.
In this study, the development of the first, internally-
controlled, competitive PCR/ELISA assay for the
diagnosis of EHV-1 infection is described. The assay
allows for multiple sample detection using end-stage,
colourimetric detection of amplicons using gB type-
specific DNP oligonucleotide probe hybridisation. The
inclusion of a control eliminates the possibility of false
negative EHV-1 results due to the co-extraction of PCR
inhibitors. The design of this competitive PCR/ELISA
diagnostic assay allows for the rapid and sensitive
detection of EHV-1 in horses which, following further
validation, may have significant potential for eliminat-
ing the occurrence of abortion storms in stud farms.
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